Crossmark

Current Status of Bone-Forming Therapies for the Management of Osteoporosis

Crossref DOI link: https://doi.org/10.1007/s40266-019-00675-8

Published Online: 2019-05-08

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sølling, Anne Sophie Koldkjær

Harsløf, Torben

Langdahl, Bente http://orcid.org/0000-0002-8712-7199
License Information

Text and Data Mining valid from 2019-05-08
More Information

Article History

First Online: 8 May 2019

Compliance with Ethical Standards

:

: No sources of funding were used in the preparation of this review.

: Torben Harsløf received lecture fees from Amgen, Astra Zeneca, and Eli Lilly. Bente Langdahl is editor-in-chief of Bone Reports and associate editor of the European Journal of Endocrinology and has received research funding to her institution from Amgen and Novo Nordisk. Bente Langdahl serves on advisory boards and speaker’s bureau for Eli Lilly, Amgen, UCB, and TEVA. Anne Sophie Koldkjær Sølling has nothing to declare.